Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Molecular Properties of Natural Bioactive Compounds Confined in Zea mays and its Application


Affiliations
1 Department of Physics, Dr. Shakuntala Misra National Rehabilitation University, Lucknow, Uttar Pradesh, India
     

   Subscribe/Renew Journal


Despite substantial progress in recent years, ample therapeutic challenges remain in the treatment of the various diseases. Addressing these challenges requires recognition of pristine classes of drugs and development of non invasive and lucrative methods to select the most appropriate therapeutic option for the disease. The present study discusses the drug property of a natural bioactive compounds contained in Zea mays and aims to establish the active principles of bioactivity The present study investigates the renoprotective properties of a natural non-protein compound pelargonidin-3-glucoside confined in Zea mays that inhibits Angiotensin-I Converting Enzyme. The compounds to be explored as better inhibitors with respect to binding of various drugs like Perindopril available in market and the interactions responsible for the bioactivity of the compound have been discussed using computational methods.

Keywords

ACE-II (Angiotensin-II Converting Enzyme), Bioactivity, LUMO Pelargonidin-3-Glucoside.
User
Subscription Login to verify subscription
Notifications
Font Size

  • H. Kierszenbaum, and L. Abraham, Histology and Cell Biology: An Introduction to Pathology, 4th ed., 2007.
  • J. D. Imig, “ACE inhibition and Bradykinin-mediated renal vascular responses: EDHF involvement,” Hypertension, vol. 43, no. 3, pp. 533-535, 2004.
  • R. E. Klabunde, “ACE-inhibitors,” Cardiovascular Pharmacology Concepts, 2009.
  • S. Suissa, T. Hutchinson, J. M. Brophy, and A. Kezouh, “ACE-inhibitor use and the long-term risk of renal failure in diabetes,” Kidney International, vol. 69, pp. 913-919, 2006.
  • E. Kaschina, and T. Unger, “Angiotensin AT1/AT2 receptors: Regulation, signalling and function,” Blood Press, vol. 12, pp. 70-88, 2003.
  • T. Morgan, and R. Renin, “Angiotensin, sodium and organ damage,” Hypertens. Res., vol. 26, pp. 349-354, 2003.
  • N. Marvin. “ChemAxon,” 2010. Available: http://www.chemaxon.com
  • O. Trott, A. J. Olson, and A. D. Vina, “Improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading,” Journal of Computational Chemistry, vol. 31, pp. 455-461, 2010.
  • M. Rarey, B. Kramer, T. Lengauer, and G. Klebe, “A fast flexible docking method using an incremental construction algorithm,” J. Mol. Biol., vol. 261, no. 3, pp. 470-489, 1996.
  • D. W. Ritchie, and V. Venkatraman, “Ultra-Fast FFT protein docking on graphics processors,” Bioinformatics, vol. 26, pp. 2398-2405, 2010.
  • E. E. Pettersen, T. D. Goddard, C. C. Huang, G. S. Couch, D. M. Greenblatt, E. C. Meng, T. E. Ferrin, and U. C. S. F. Chimera, “A visualization system for exploratory research and analysis,” J. Comput. Chem., vol. 13, pp. 1605-1612, 2004.
  • SIMCYP. Available: http://www.simcyp.com/ProductServices/FreeADMETools/
  • Opentox. Available: http://www.opentox.org/toxicity-prediction
  • M. W. Schmidt, K. K. Baldridge, J. A. Boatz, S. T. Elbert, M. S. Gordon, J. H. Jensen, S. Koseki, N. Matsunaga, K. A. Nguyen, S. Su, T. L. Windus, M. Dupuis, and J. A. Montgomery Jr., “General atomic and molecular electronic structure system,” J. Comput. Chem., vol. 14, no. 11, pp. 1347-1363, 1993.
  • L. Skripnikov, “Chemissian: Version 2, 2005-2011,” 2005. Available: www.chemissian.com
  • M. Suenaga, “Facio: New computational chemistry environment for PC GAMESS,” Journal of Computer Chemistry, Japan, vol. 4, no. 1, pp. 25-32, 2005.
  • A. C. Gaudio, “MoCalc interface for molecular calculation, Version-2.2.11,” Federal University of Espirito, Santo, 2003-2005.
  • J. P. Bounhoure, G. Bottineau, and P. Lechat, “Value of perindopril in the treatment of chronic congestive heart failure: Multicentre double-blind placebo-controlled study,” Clin. Exp. Hypertens., vol. A11, no. 2, pp. 575-586, 1989.
  • Y. S. Moreno, G. S. Sánchez, and D. R. Hernandez, “Characterization of anthocyanin extracts from maize kernels,” J. Chromatogr. Sci., vol. 43, no. 9, pp. 483-487, 2005.
  • S. M. Abdel-Aal el, J. C. Young, and I. Rabalski, “Anthocyanin composition in black, blue, pink, purple, and red cereal grains,” J. Agric. Food. Chem., vol. 54, no. 13, pp. 4696-4704, 2006.

Abstract Views: 267

PDF Views: 7




  • Molecular Properties of Natural Bioactive Compounds Confined in Zea mays and its Application

Abstract Views: 267  |  PDF Views: 7

Authors

A. K. Mishra
Department of Physics, Dr. Shakuntala Misra National Rehabilitation University, Lucknow, Uttar Pradesh, India

Abstract


Despite substantial progress in recent years, ample therapeutic challenges remain in the treatment of the various diseases. Addressing these challenges requires recognition of pristine classes of drugs and development of non invasive and lucrative methods to select the most appropriate therapeutic option for the disease. The present study discusses the drug property of a natural bioactive compounds contained in Zea mays and aims to establish the active principles of bioactivity The present study investigates the renoprotective properties of a natural non-protein compound pelargonidin-3-glucoside confined in Zea mays that inhibits Angiotensin-I Converting Enzyme. The compounds to be explored as better inhibitors with respect to binding of various drugs like Perindopril available in market and the interactions responsible for the bioactivity of the compound have been discussed using computational methods.

Keywords


ACE-II (Angiotensin-II Converting Enzyme), Bioactivity, LUMO Pelargonidin-3-Glucoside.

References